What podcasts say about Jeremy Scheppers
Every statement, with the speaker, the exact quote and the moment it was said.
What Jeremy Scheppers has said on podcasts
16 statements · 13 positive · 1 mixed · 2 neutral
Granted patents provide market exclusivity for pharmaceutical programs.
“what that does then, it kind of allows exclusivity on the market”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 32:46
Poolbeg’s broad POLB-001 patent position is attractive to potential partners.
“we're kind of first movers here, and having a nice broad patent, I think, is pretty attractive to our potential partners”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 33:39
Poolbeg aims to enroll approximately 30 patients in its POLB-001 trial.
“our ultimate goal is to kind of build this up to roughly or approximately 30 patients”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 35:23
Poolbeg expects trial data to enable partnering of POLB-001.
“we believe that we'll be able to partner the program because we've started really productive discussions”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 35:30
Similar mechanisms likely drive cytokine release syndrome across other immunotherapies.
“our belief is that similar mechanisms drive the CRS with other drugs”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 41:56
Preventing cytokine release syndrome represents a multibillion-dollar market.
“this is a multi-billion dollar space, a multi-billion dollar market”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 43:19
Poolbeg’s fundraising provides cash runway through the second quarter of 2028.
“gives us runway into Q2 of 2028”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 44:37
Pharmaceutical companies may pay substantial sums to acquire POLB-001 after positive data.
“they will, you know, write big checks to bring this in-house”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 45:44
Poolbeg expects significant upfront payments from licensing POLB-001.
“we will generate significant upfront payments for accessing the program”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 46:23
Poolbeg expects POLB-001 to reduce or eliminate cytokine release syndrome.
“we're going to reduce or eliminate CRS”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 48:47
No treatment is currently approved to prevent CRS; Poolbeg hopes to be first.
“There's no— nothing is approved to prevent CRS right now. We hope to be the first there.”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 50:26
Talon’s initial field results increased confidence in Eagle Lake’s discovery potential.
“Has it increased our confidence? I mean, absolutely.”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 1:11:54
Talon’s Moss Knoll prospect returned over three metres grading above one gram.
“we had over 3 meters at over a gram”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 1:13:28
Talon’s initial drill holes will likely reach approximately 150 metres.
“we're probably going to be somewhere in and around that depth”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 1:15:21
Archean greenstone lode-gold systems typically improve with depth.
“typically these kind of greenstone Archean lode gold systems get better with depth”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 1:16:20
Surface outcrops across Eagle Lake consistently contain gold, often at strong grades.
“everywhere it does appear at surface, it's got gold in it, and quite often very good levels of gold as well”
Open the episode · S11 Ep93: The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAXListen at 1:21:03
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.